Business Context and Reporting Period
This Form 8-K was filed by AMHN, Inc. (referenced in metadata as Therapeuticsmd, Inc.) on September 8, 2011. The report details the entry into a Material Definitive Agreement and the unregistered sale of equity securities. The filing is contingent upon the closing of a previously reported Merger Agreement involving VitaMedMD, LLC.
Key Financial Metrics and Transaction Details
- Transaction Type: Stock Purchase Agreement for unregistered equity securities.
- Purchaser: Pernix Therapeutics, LLC.
- Shares Issued: 2,631,579 shares of Common Stock.
- Purchase Price: $0.38 per share.
- Total Proceeds: $1,000,000.
- Regulatory Basis: Exemption from registration under Section 4(2) of the Securities Act of 1933.
The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity metrics for the reporting period.
Material Changes and Conditions
The issuance of shares is conditional. The closing of the Stock Purchase Agreement is scheduled to occur on the business day following the closing of the Merger Agreement dated July 18, 2011. If the transaction does not close by October 31, 2011 (unless extended by mutual agreement), the agreement will terminate with no liability to either party.
Guidance, Outlook, and Restrictions
Lock-Up Agreement: In connection with the purchase, Pernix Therapeutics, LLC entered into a Lock-Up Agreement with the following terms:
- Initial Restriction: No sale, assignment, or transfer of shares for 12 months from the agreement date.
- Subsequent Restriction: For the 12 months following the initial period, Pernix may not sell more than 5% of the shares per quarter.
Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from expectations due to various factors. The company does not undertake an obligation to update these statements.
Investor Verification Checklist
- Verify the status of the Merger Agreement with VitaMedMD, LLC, as the stock purchase is contingent upon its closing.
- Confirm the actual closing date of the transaction to ensure it occurred before the October 31, 2011 deadline.
- Review the full text of the Stock Purchase Agreement and Lock-Up Agreement (Exhibits 10.01 and 10.02) for additional covenants.
- Monitor the company's capital structure for the dilution impact of the 2,631,579 new shares.